BACKGROUND: The primary cause of long-term failure of bioprosthetic valves is structural @entity340 due to tissue @entity730 . A novel anti- @entity730 technology platform was developed that may irreversibly block @entity460 binding sites in bioprosthetic valves. METHODS: Twenty @entity1 with severe @entity472 underwent isolated aortic valve replacement using a bioprosthetic valve treated with the novel anti- @entity730 technology. Mean @entity1 age and body mass index was 73.7    4.8 years and 30.1    5.8 kg-m     , respectively. Females comprised 65% of the @entity1 population and 30% of the population was in NYHA Class III/IV. Other baseline characteristics included @entity101 (90%), @entity407 (75%), @entity6 (35%), @entity177 (25%), @entity358 (10%), and @entity583 (10%,). @entity1 were followed-up upto 1 year. Hemodynamic performance was evaluated by echocardiography. All complicatios were recorded. RESULTS: There was one early death on postoperative day 5. No other coplications were noted up to discharge, Follow-up at 3-6 months and at 1 year were both 100%. At 1 year, no valve-related mortality, @entity21375 , major @entity2478 (>2+), @entity1031 , @entity548 , @entity340 , and reoperation were observed. Mean effective orifice area increased from 1.0    0.5cm   at baseline to 1.8    0.5 cm   at 1 year. Mean gradient decreased from 54.8(   21.2 mmHg) at baseline to 11.3(   3.4 mmHg) at 1 year. CONCLUSIONS: This early clinical experience using an aortic bioprosthetic valve treated with a novel anti- @entity730 tissue processing technology demonstrated excellent valve performance, durability, and safety. No valve related complications were noted. Longer-term follow-up is needed to verify these promising results.

Aortic valve replacement with a novel anti- XXXX technology platform.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity548 :: ('MESH:D006470', 'Disease') :: ['major bleeding'] @entity2478 :: ('MESH:D019559', 'Disease') :: ['paravalvular leak'] @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic stenosis'] @entity730 :: ('MESH:D002114', 'Disease') :: ['calcification'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary disease'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic events'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity340 :: ('MESH:D006349', 'Disease') :: ['prosthetic valve endocarditis', 'valve deterioration'] @entity21375 :: ('MESH:C536677', 'Disease') :: ['SVD']
@entity730 :: (MESH:D002114,Disease) :: ['calcification']
